Read the article: https://www.iptonline.com/collections/ipt-winter-2025/building-fine-tuning-capabilities-for-co-folding-models-in-pharm
Co-folding models perform well on benchmarks but struggle on novel targets. Real impact comes from building internal capabilities: benchmarking on proprietary data, fine-tuning where needed, and extending generalisability. Read Robin Röhm's IPT piece to learn more

Read the article: https://www.iptonline.com/collections/ipt-winter-2025/building-fine-tuning-capabilities-for-co-folding-models-in-pharm

We rebuilt the SandboxAQ affinity head inside ApherisFold and fine-tuned it on 49 JAK2 macrocycles. Architectural changes alone lifted Spearman ranking from 0.418 to 0.60; fine-tuning then pushed validation Pearson from 0.23 to 0.76, mostly by correcting how the model handled inactives.

Delivering a state-of-the-art federated co-folding model across five pharma companies in record time

Co-folding models help lead optimization by predicting binding modes, filtering weak candidates before synthesis, and improving compound prioritization through benchmarking, fine-tuning, and expert review.
NEWSLETTER
A quaterly briefing on operationalizing and customizing co-folding, ADMET and antibody developability models. Written by Robin Röhm, co-founder and CEO at Apheris.

Robin Röhm
Co-Founder & CEO
© 2026 Apheris AI GmbH. All rights reserved.